Expanding Cessation Pharmacotherapy Via Videoconference Educational Outreach to Prescribers

Pharmacotherapy of smoking cessation.

Tobacco use is the number one cause of preventable diseases in the United States. Smoking accounts for more than 400,000 deaths yearly and 30% of all cancer deaths. Primary care physicians have access to 70% of smokers, approximately 60% of whom are perceived to be in excellent health. Recent advances in the pharmacotherapy of nicotine addiction, including nicotine nasal spray, nicotine inhaler...

Educational outreach to improve vaccination uptake.

Proactive outreach strategies to connect smokers with tobacco cessation treatment.

38. Rigotti NA, Bitton A, Kelley JK, Hoeppner BB, Levy DE, Mort E. Offering population-based tobacco treatment in a healthcare setting: a randomized controlled trial. Am J Prev Med. 2011; 41(5):498-503. 39. Fraser D, Christiansen BA, Adsit R, Baker TB, Fiore MC. Electronic health records as a tool for recruitment of participants’ clinical effectiveness research: lessons learned from tobacco ces...

Smoking cessation: benefits versus risks of using pharmacotherapy to quit.

S moking cessation benefits health and lengthens life expectancy at any age. With that rationale, smoking cessation figures centrally in comprehensive tobacco control initiatives, including the recommendations of the US Preventive Services Task Force and the World Health Organization. 3,4 The population of the United States has recognized the personal benefits of stopping smoking and, at presen...

Varenicline: a novel pharmacotherapy for smoking cessation.

Varenicline is an orally administered small molecule with partial agonist activity at the alpha4beta2 nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the European Medicines Agency of the EU in 2006 as an aid to smoking cessation. Subsequently, varenicline has been approved in over 80 other countries. Varenicline is almost entirely absorbed following oral admini...